Shares of Immunome, Inc. (IMNM) have gained 1.1% over the past four weeks to close the last trading session at $8.49, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of$24.50 indicates a potential upside of 188.6%.The mean estimate comprises eight short-term price targets with a standard deviation of $5.76. While the lowest estimate of$20 indicates a 135.6% increase from the curr ...